Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Na ïve Patients

The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized due to technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M. Mark Source Type: research